Candida auris is a species of fungus that grows as yeast. It is one of the few species of the genus Candida which cause candidiasis in humans. Often, candidiasis is acquired in hospitals by patients with weakened immune systems. C.auris can cause invasive candidiasis (fungemia) in which the bloodstream, the central nervous system, and internal organs are infected. It has attracted widespread attention because of its multiple drug resistance. Treatment is also complicated because it is easily misidentified as other Candida species.
Candida auris was first described in 2009 after it was isolated from the ear canal of a 70-year-old Japanese woman at the Tokyo Metropolitan Geriatric Hospital in Japan. In 2011, South Korea saw its first cases of disease-causing C.auris. Reportedly, this spread across Asia and Europe, and first appeared in the U.S. in 2013.
DNA analysis of four distinct but drug-resistant strains of Candida auris indicate an evolutionary divergence taking place at least 4,000 years ago, with a common leap among the four varieties into drug-resistance possibly linked to widespread azole-type antifungal use in agriculture. However, explanations for its emergence remain speculative.
First identified in 2009, Candida auris is a species of ascomycetous fungus of the genus Candida that grows as a yeast. Its name comes from the Latin word for ear, aus (genitive auris).[1] It forms smooth, shiny, whitish-gray, viscous colonies on growth media. Microscopically, cells are ellipsoid in shape.
Candida auris has attracted increased clinical attention because of its multiple drug resistance.[2] [3] [4]
In vitro, more than 90% of C.auris isolates are resistant to fluconazole[5] and a range of 3–73% of C.auris isolates are resistant to voriconazole,[6] while other triazoles (posaconazole, itraconazole, and isavuconazole) display better activity. Of isolates, 13% to 35% were reported resistant to amphotericin B; however, most isolates are susceptible to echinocandins.
Treatment is complicated because C.auris is easily misidentified as various other Candida species.[7] [8] A brief outline of its clinical relevance, understandable by general audiences, was published by the Center for Infectious Disease Research and Policy at the University of Minnesota.[9]
According to papers published from 2011 to 2016, mortality of people with C.auris bloodstream infections (BSI) ranged from 30 to 60%.[10] Many of these people had other serious illnesses and conditions (comorbidities) that increased their risk of death.[11]
there is no human vaccine against Candida auris.[12] Experiments involving the NDV-3A vaccine have successfully immunized mice against the fungus.[13] The vaccine also improved the protective efficacy of the antifungal drug micafungin against C. auris infection in the mouse bloodstream.[14]
Several draft genomes from whole genome sequencing have been published.[15] C.auris has a genome size of 12.3–12.5 with a GC-content of 44.5–44.8%. The C.auris genome was found to encode several genes for the ABC transporter family, a major facilitator superfamily, which helps to explain its multiple drug resistance. Its genome also encodes virulence-related gene families such as lipases, oligopeptide transporters, mannosyl transferases and transcription factors which facilitate colonization, invasion, and iron acquisition. Another factor contributing to antifungal resistance is the presence of a set of genes known to be involved in biofilm formation.
More studies are needed to determine whether the phylogenetic divergence of C.auris clones exhibits region-specific patterns of invasiveness, virulence, and/or drug resistance.
The phylogenetics of C.auris suggest distinct genotypes exist in different geographical regions with substantial genomic diversity.[16] A variety of sequence-based analytical methods have been used to support this finding.
Whole genome sequencing and analyses of isolates from Pakistan, India, South Africa, Venezuela, Japan, and previously sequenced C.auris genomes deposited in the National Center for Biotechnology Information's Sequence Read Archive[17] identified a distinct geographic distribution of genotypes.[18] Four distinct clades separated by tens of thousands of single-nucleotide polymorphisms were identified. The distribution of these clades segregated geographically to South Asia (India and Pakistan), South Africa, Venezuela, and Japan with minimal observed intraregion genetic diversity.
Amplified fragment length polymorphism analysis of C.auris isolates from the United Kingdom, India, Japan, South Africa, South Korea, and Venezuela suggested that the London isolates formed a distinct cluster compared to the others.[19]
Comparison of ribosomal DNA sequences of C.auris isolates from Israel, Asia, South Africa, and Kuwait found that the strains from Israel were phylogenetically distinct from those from the other regions.[20] Chatterjee et al. wrote in 2015, "Its actual global distribution remains obscure as the current commercial methods of clinical diagnosis misidentify it as C.haemulonii."
Candida auris was first described in 2009 after it was isolated from the ear canal of a 70-year-old Japanese woman at the Tokyo Metropolitan Geriatric Hospital in Japan. It was isolated based on its ability to grow in the presence of the fungicide micafungin, an echinocandin class fungicide. Phenotypic, chemotaxonomic and phylogenetic analyses established C.auris as a new strain of the genus Candida.[21]
The first three cases of disease-causing C.auris were reported from South Korea in 2011.[22] Two isolates had been obtained during a 2009 study and a third was discovered in a stored sample from 1996. All three cases had persistent fungemia, i.e. bloodstream infection, and two of the patients subsequently died due to complications. Notably, the isolates initially were misidentified as Candida haemulonii and Rhodotorula glutinis using standard methods, until sequence analysis correctly identified them as C.auris. These first cases emphasize the importance of accurate species identification and timely application of the correct antifungal for the effective treatment of candidiasis with C.auris.
During 2009–2011, 12 C.auris isolates were obtained from patients at two hospitals in Delhi, India.[23] The same genotype was found in distinct settings: intensive care, surgical, medical, oncologic, neonatal, and pediatric wards, which were mutually exclusive with respect to health care personnel. Most had persistent candidemia and a high mortality rate was observed. All isolates were of the same clonal strain, however, and were only identified positively by DNA sequence analysis. As previously, the strain was misidentified with established diagnostic laboratory tests. The Indian researchers wrote in 2013 that C.auris was much more prevalent than published reports indicate since most diagnostic laboratories do not use sequence-based methods for strain identification.
The fungus spread to other continents and eventually, a multi-drug-resistant strain was discovered in Southeast Asian countries in early 2016.[24]
The first report of a C.auris outbreak in Europe was an October 2016 in Royal Brompton Hospital, a London cardio-thoracic hospital. In April 2017, CDC director Anne Schuchat named it a "catastrophic threat".[25] the CDC had reported 77 cases in the United States. Of these, 69 were from samples collected in New York and New Jersey.[26]
the number of cases of people having contracted C.auris in the United States had risen to 806, with 388 reported in New York, 137 in New Jersey and 227 in Illinois, according to the CDC.[27]
Since it was first observed in the United Kingdom, it has spread to more than 20 NHS Trust hospitals and infected 200 people.[28]
, the CDC has documented cases of C.auris from the following countries: Australia, Austria, Belgium, Canada, China, Colombia, France, Germany, India, Iran, Israel, Japan, Kenya, Kuwait, Malaysia, Mexico, the Netherlands, Norway, Oman, Pakistan, Panama, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, the United Arab Emirates, the United Kingdom, the United States, and Venezuela.
Candida auris fungus (C. auris) is a multi-drug–resistant fungal infection that spreads in hospitals and is extremely deadly—killing as many as one in three who get it.—Abby Haglage of Yahoo! Lifestyle,[29] citing the Centers for Disease Control and Prevention[30]
Arturo Casadevall, MD, PhD, and Molecular Microbiology and Immunology chair at Johns Hopkins Bloomberg School of Public Health stated:
What this study suggests is this is the beginning of fungi adapting to higher temperatures, and we are going to have more and more problems as the century goes on. Global warming will lead to selection of fungal lineages that are more thermally tolerant.[29]
The COVID-19 pandemic has taken resources away from combating and tracking the fungus, which has led to outbreaks.[31] Shortages of personal protective equipment forced medical personnel to reuse of gowns and masks during the pandemic, which has contributed to the fungi's spread.[31] In 2021, the CDC identified strains of Candida auris that were immune to all existing medications used to treat fungal infections.[32] Research published in Annals of Internal Medicine tracking the spread of Candida auris from 2019 through 2021 revealed the fungus was present in over half of American states.[33] [34] [35]
Antimicrobial resistance in general is an increasingly common phenomenon. In 2010, two million people were reported to have contracted resistant infections in the United States 23,000 fatally. "[M]ore recent estimates from researchers at Washington University School of Medicine put the death toll at 162,000. Worldwide fatalities from resistant infections are estimated at 700,000 per year.[36] C. auris is one of the many microbial contributors to this global AMR estimation.